The Indian Patent Office is forcing the pharmaceutical manufacturer Bayer to hand over the patent for its anti-cancer medication Nexavar. It is the first time a judgment to grant a compulsory license has been issued under Indian patent law regulations. Dr. Jens Hammer represents pharmaceutical companies from Europe and the USA. In the interview, the patent attorney examines the consequences of the decision, providing information on compulsory license procedures, while advising that pharmaceutical companies in particular need to review license-related inquiries of Indian manufacturers of generic drugs.